Main public logs

Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

• 19:30, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1202.jpeg
• 19:30, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1202.jpeg
• 19:28, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1200.jpeg
• 19:28, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1200.jpeg
• 19:24, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1214.jpeg
• 19:24, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1214.jpeg
• 05:30, 12 May 2024 Kosar Doraghi talk contribs created page Somatrogon-ghla (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.con] |genericName=somatrogon-ghla |aOrAn=a |drugClass=human growth hormone analog |indicationType=treatment |indication=pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone |hasBlackBoxWarning=Yes |adverseReactions=injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, v...")
• 05:15, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1198.jpeg
• 05:15, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1198.jpeg
• 05:13, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1215.jpeg
• 05:13, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1215.jpeg
• 20:21, 11 May 2024 Rithish Nimmagadda talk contribs created page Elfabrio (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio...")
• 19:36, 11 May 2024 Rithish Nimmagadda talk contribs created page Exxua (Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}")
• 13:10, 9 May 2024 Rithish Nimmagadda talk contribs created page Epcoritamab-bysp (Created page with "{{DrugProjectFormSinglePage |authorTag=VSRN }}")
• 10:37, 9 May 2024 Hafiza Amna Qadeer talk contribs created page FUTIBATINIB (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER, MD |OTC=Yes |genericName=FUTIBATINIB |aOrAn=a |drugClass=Kinase Inhibitor |indicationType=treatment |indication=* of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. |adverseReactions=1* Nail Toxicity, stomatitis, dry skin, dry eye, alopecia 2* Musculos...")
• 04:57, 9 May 2024 Alen Antony talk contribs created page Sotagliflozin (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}")
• 21:32, 8 May 2024 Kosar Doraghi talk contribs created page EXXUA (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Gepirone |aOrAn=a |drugClass=extended-release tablets |indicationType=treatment |indication=major depressive disorder (MDD) in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, nausea, insomnia, abdominal pain, and dyspepsia |blackBoxWarningTitle=WARNING: SUICIDAL THOUGHTS AND BEHAVIORS |blackBoxWarningBody=SEE FULL PRESCRIBING INFORMATION FOR...")
• 21:27, 8 May 2024 Kosar Doraghi talk contribs created page File:IMG 1195.jpeg
• 21:27, 8 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1195.jpeg
• 21:26, 8 May 2024 Kosar Doraghi talk contribs created page File:IMG 1196.jpeg
• 21:26, 8 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1196.jpeg
• 21:19, 8 May 2024 Kosar Doraghi talk contribs created page File:IMG 1194.jpeg
• 21:19, 8 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1194.jpeg
• 17:11, 8 May 2024 Imam Ali Shah talk contribs created page File:Screenshot (245).jpg
• 17:11, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Screenshot (245).jpg
• 17:02, 8 May 2024 Imam Ali Shah talk contribs created page File:RCR logo.png
• 17:02, 8 May 2024 Imam Ali Shah talk contribs uploaded File:RCR logo.png
• 16:30, 8 May 2024 Imam Ali Shah talk contribs uploaded a new version of File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg (Pre-contrast CT scan of the abdomen and pelvis depicts an irregular nodular margin of the liver (green arrowhead), hypertrophy of the caudate lobe (orange arrow), and the presence of ascites (red arrow).)
• 16:21, 8 May 2024 Imam Ali Shah talk contribs created page File:Portal-venous phase CT scan of the abdomen and pelvis in Liver Cirrhosis.png
• 16:21, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Liver Cirrhosis.png
• 16:19, 8 May 2024 Imam Ali Shah talk contribs created page File:Portal-venous phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
• 16:19, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
• 16:18, 8 May 2024 Imam Ali Shah talk contribs created page File:Arterial phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
• 16:18, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Arterial phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
• 16:17, 8 May 2024 Imam Ali Shah talk contribs created page File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
• 16:17, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
• 14:44, 8 May 2024 Rithish Nimmagadda talk contribs created page Template:VSRN (Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]")
• 14:20, 8 May 2024 Rithish Nimmagadda talk contribs created page User:Rithish Nimmagadda (Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India")
• 14:10, 8 May 2024 Rithish Nimmagadda talk contribs created page FRUZAQLA (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma...")
• 13:32, 8 May 2024 Rithish Nimmagadda talk contribs created page Fruzaqla (Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}")
• 01:53, 8 May 2024 Edzelco talk contribs created page File:LOQTORZI Dosage.png
• 01:53, 8 May 2024 Edzelco talk contribs uploaded File:LOQTORZI Dosage.png
• 17:27, 7 May 2024 Alen Antony talk contribs created page Zuranolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...")
• 22:57, 3 May 2024 Kosar Doraghi talk contribs created page Xacduro- sulbactam and durlobactam (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin...")
• 18:20, 3 May 2024 Alen Antony talk contribs created page Perfluorhexyloctane (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}")
• 15:29, 2 May 2024 Alen Antony talk contribs created page Trofinetide (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}")
• 03:29, 2 May 2024 Alen Antony talk contribs created page Zavegepant (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic...")
• 21:51, 1 May 2024 Alen Antony talk contribs created page Omaveloxolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=omaveloxolone }}")
• 15:46, 1 May 2024 Kosar Doraghi talk contribs created page Nirsevimab (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=Nirsevimab |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season |hasBlackBo...")
• 15:31, 1 May 2024 Kosar Doraghi talk contribs created page File:IMG 1185.jpeg